Skip to main content

Table 1 Patient and [18F]PSMA-1007-PET/CT characteristics

From: Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer

Characteristics Value   Total number of available observations
Age (years)    175
 Mean ± SDa 69 ± 8.8   
 Median (range) 70 (46–88)   
Neoadjuvant treatment 13 9.5% 137
Primary treatment    137
 Radical prostatectomy 107 78%  
 EBRTb 12 8.8%  
 Androgen deprivation therapy 10 7.3%  
 Brachytherapy 7 5.1%  
 High Intensity Focused Ultrasound 1 0.7%  
Adjuvant external beam radiation therapy 30 22% 137
Prior androgen deprivation therapy 83 61% 137
Ongoing androgen deprivation therapy 42 24% 175
Salvage therapy    137
 No salvage surgery or EBRT 76 55%  
 Salvage surgery 13 9.5%  
 EBRT 39 28%  
 Salvage surgery and EBRT 9 6.6%  
Pathologic primary tumour staging    107
 pT2 44 41%  
 pT3 60 56%  
 pT4 3 2.8%  
Pathologic regional lymph node staging    79
 pN0 57 72%  
 pN1 22 28%  
Positive surgical margin at radical prostatectomy 41 41% 101
Number of positive lymph nodes removed at primary treatment    78
 Median (range) 0 (0–18)   
Gleason score    136
 5 1 0.7%  
 6 9 6.6%  
 7 67 49%  
 8 33 24%  
 9 26 19%  
PSA value after radical prostatectomy (ng/ml)    102
 Mean ± SD 0.4 ± 1.6   
 Median (range) 0.04 (0–12)   
PSA value at PET scan (ng/ml)    175
 Mean ± SD 11.1 ± 47.5   
 Median (range) 1.6 (0.07–429)   
PSA doubling time (months)    171
 Mean ± SD 9.5 ± 10.1   
 Median (range) 6.7 (0.8–96.9)   
PSA velocity (ng/ml/month)    171
 Mean ± SD 1.6 ± 9.8   
 Median (range) 0.1 (0–114.5)   
  1. aStandard deviation
  2. bExternal beam radiation therapy